Introduction
============

"'Individuality in universality is the plan of creation'. -Swami Vivekananda"

Objective and quantitative markers would permit better and more precise assessment, tracking and prediction of suicidal risk, which would enable preventive therapeutic interventions.^[@bib1],\ [@bib2],\ [@bib3]^ Previous work by our group has identified blood biomarkers and phenotypic predictors for suicide risk in men^[@bib4]^ and separately in women,^[@bib5]^ showing some gender similarities as well as differences. An essential question remained to be answered, of high relevance for developing this area of research and carrying it to full clinical applicability: would a quest for more universal predictors or a quest for more personalized predictors be more productive? We endeavored to answer this question through our current work. First, we sought to investigate whether blood gene expression biomarkers can be identified that are more universal in nature, working across psychiatric diagnoses and genders, starting with a powerful longitudinal within-participant^[@bib6]^ design and using larger cohorts than in previous studies^[@bib7],\ [@bib4],\ [@bib5]^ ([Figure 1](#fig1){ref-type="fig"}). Second, we identified subtypes of suicidality based on mental state (anxiety, mood and psychosis) at the time of high suicidal ideation.^[@bib8],\ [@bib9],\ [@bib10]^ Third, we used a more personalized approach, by gender and diagnosis, with a focus on the highest clinical risk group, male bipolars. We examined the ability of the universal candidate biomarkers to predict suicidal ideation (SI) and future hospitalizations for suicidality, in completely independent cohorts, in everybody, as well as divided by subtypes, and personalized by gender and diagnosis. We also directly compared the universal biomarkers with biomarkers discovered using male bipolars only, for ability to predict SI and future hospitalizations for suicidality in independent cohorts of male bipolars.

Per our *a priori* design described in previous studies,^[@bib4],\ [@bib5]^ we also combined the top biomarkers with scores obtained with a clinical information measure of suicide risk (Convergent Functional Information for Suicidality, CFI-S), as well as with scores for anxiety and mood obtained with an 11-item visual analog scale (Simplified Affective State Scale, SASS),^[@bib4],\ [@bib5],\ [@bib8]^ to obtain a broader spectrum predictor (UP-Suicide) that puts the biomarkers in the context of the person's life and his/hers mental state. The triggers for suicide may be the individual's perceptions of being unsuccessful, with no future, suffering, damaged, along with mental frailty, addictions and cultural exposure to suicide. Our CFI-S scale captures such information about who a person is, and along with the SASS scale that captures mental state information and permits classification in subtypes, they add a broader context to the objective blood biomarker predictors we have uncovered (Figure 5). Of note, these scales do not ask about SI, as individuals who want to commit suicide may not always share that information, for fear of being stopped.

We also used the lists of top biomarkers we identified as a window into the biology of suicidality, by conducting biological pathways and network analyses, and by looking at co-morbidity with other disorders that may predispose or create a vulnerability to suicidality.

In addition, we leveraged these lists for therapeutics and drug discovery purposes, to see whether some of the biomarkers we identified are modulated by existing compounds used to treat suicidality and also to conduct bioinformatics drug repurposing analyses to discover new drugs and natural compounds that may be useful for treating suicidality.

Finally, we integrated the totality of evidence we have generated in this study and available in the literature to date, to prioritize biomarkers for future clinical studies in the field.

Materials and methods
=====================

Cohorts
-------

We used three independent cohorts: discovery (a live psychiatric participants cohort), validation (a postmortem coroner's office suicide completers cohort) and testing (an independent live psychiatric participants test cohort for predicting SI and for predicting future hospitalizations for suicidality) ([Figure 1a](#fig1){ref-type="fig"}).

Similar to our previous studies,^[@bib7],\ [@bib4],\ [@bib5]^ the live psychiatric participants are part of a larger longitudinal cohort of adults that we are continuously collecting. Participants are recruited from the patient population at the Indianapolis VA Medical Center and Indiana University School of Medicine. All participants understood and signed informed consent forms detailing the research goals, procedure, caveats and safeguards, per Institutional Review Board-approved protocol. Participants completed diagnostic assessments by an extensive structured clinical interview---Diagnostic Interview for Genetic Studies---at a baseline visit, followed by up to six testing visits, 3--6 months apart or whenever a new psychiatric hospitalization occurred. At each testing visit, they received a series of psychiatric rating scales, including the Hamilton Rating Scale for Depression-17, which includes a SI rating item ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}), and their blood was drawn. We collected whole blood (10 ml) in two RNA-stabilizing PAXgene tubes, labeled with an anonymized ID number and stored at −80 °C in a locked freezer until the time of future processing. Whole-blood RNA was extracted for microarray gene expression studies from the PAXgene tubes, as detailed below.

For this study, our within-participant discovery cohort, from which the biomarker data were derived, consisted of 66 participants (49 males and 17 females) with psychiatric disorders and multiple testing visits, who each had at least one diametric change in SI scores from no SI to high SI, or vice versa, from one testing visit to another. There were 2 participants with 6 visits each, 3 participants with 5 visits each, 5 participants with 4 visits each, 34 participants with 3 visits each and 22 participants with 2 visits each, resulting in a total of 193 blood samples for subsequent gene expression microarray studies ([Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"} and S1).

Our postmortem cohort, in which the top biomarker findings were validated for behavior, consisted of 38 male and 7 female violent suicide completers obtained through the Marion County coroner's office ([Table 1](#tbl1){ref-type="table"}). We required a last observed alive postmortem interval of 24 h or less and the cases selected had to have completed suicide by means other than overdose, which could affect gene expression. Thirty-one participants completed suicide by gunshot to head or chest, 12 by asphyxiation, 1 by slit wrist and 1 by electrocution. Next of kin signed informed consent at the coroner's office for donation of blood for research.

Our independent test cohort for predicting SI ([Table 1](#tbl1){ref-type="table"}) consisted of 184 male and 42 female participants with psychiatric disorders, demographically matched with the discovery cohort, with one or multiple testing visits in our lab, with either no SI, intermediate SI or high SI, resulting in a total of 226 blood samples in which whole-genome blood gene expression data were obtained ([Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"} and S1).

Our test cohort for predicting future hospitalizations ([Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"} and S1) is a subset (170 males and 24 females) of the independent test cohort for which we had longitudinal follow-up with electronic medical records. The participants' subsequent number of psychiatric hospitalizations, with or without suicidality (ideation or attempt), was tabulated from electronic medical records. Participants were evaluated for the presence of future hospitalizations for suicidality and for the frequency of such hospitalizations. A hospitalization was deemed to be without suicidality if suicidality was not listed as a reason for admission and no SI was described in the admission and discharge medical notes. Conversely, a hospitalization was deemed to be due to suicidality if suicidal acts or intent were listed as a reason for admission and/or SI was described in the admission and discharge medical notes.

Complete Materials and Methods are available in the [Supplementary Information](#sup1){ref-type="supplementary-material"}. Of note, all genomic and phenomic data was normalized (z-scored) by gender and psychiatric diagnosis before being combined and analyzed.

Results
=======

Step 1: Discovery
-----------------

We used a powerful within-participant longitudinal discovery approach to identify genes that: (1) change in expression in blood between no SI and high SI states; (2) track the SI state across visits in a participant; and (3) track the SI state in multiple participants. We used a longitudinally followed cohort of participants that showed diametric changes in SI between at least two testing visits (*n*=66 participants out of a cohort of 293 men and women psychiatric disorder participants followed longitudinally, with diagnoses of bipolar disorder, depression, mood disorder nos, schizophrenia, schizoaffective disorder, psychosis nos and post-traumatic stress disorder). Using our 33% of maximum raw score threshold (internal score of 1 pt),^[@bib4],\ [@bib5]^ we had 10 468 unique probesets from Affymetrix Absent/Present (AP) analyses and Differential Expression (DE) analyses ([Figure 1d](#fig1){ref-type="fig"}). These were carried forward to the prioritization step. This represents approximately a fivefold enrichment of the 54 625 probesets on the Affymetrix array.

We also examined in the discovery cohort whether subtypes of suicidality can be identified based on mental state at the time of high SI visits, using two-way hierarchical clustering with anxiety, mood and psychosis measures. The SI state self-report may be more reliable in this cohort, as the participants demonstrated the aptitude and willingness to report different and diametric SI states. We uncovered four potential subtypes of suicidality: high anxiety, low mood, co-morbid and non-affective (psychotic) ([Figure 1c](#fig1){ref-type="fig"}). These subtypes need to be tested in independent cohorts for practical utility, diagnostic and therapeutic.

Step 2: Prioritization
----------------------

We used a Convergent Functional Genomics approach to prioritize the candidate biomarkers identified in the discovery step (internal score of ⩾1 pt) by using all the published prior independent evidence in the field ([Figure 1e](#fig1){ref-type="fig"}). There were 583 probesets that had a Convergent Functional Genomics score (combined internal and external score) of 4 and above. These were carried forward to the validation step. This represents approximately a 100-fold enrichment of the probesets on the Affymetrix array.

Step 3: Validation
------------------

Next, we validated for suicidal behavior these prioritized biomarkers, in a demographically matched cohort of men and women suicide completers from the coroner's office (*n*=45), by assessing which markers were stepwise changed in expression from no SI to high SI to suicide completers ([Figure 1](#fig1){ref-type="fig"}). Two hundred and seventy-four probesets were non-stepwise changed and 309 were stepwise changed. Of these, 148 survived Bonferroni correction for all the 583 probesets validated. This represents approximately a 500-fold enrichment of the probesets on the Affymetrix array.

Step 4: Testing for diagnostics
-------------------------------

We tested for diagnostic ability in independent cohorts two overlapping sets of biomarkers: the universal Top Dozen biomarkers (composed of the top increased and decreased biomarkers from AP and from DE from each step: discovery, prioritization and validation) ([Table 2](#tbl2){ref-type="table"}), as well as all the universal Bonferroni biomarkers, that survived correction for multiple comparisons after the validation step ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). The biomarkers were tested individually (the 12 biomarkers from the Top Dozen list and 148 biomarkers from the Bonferroni list), as well as in panels (BioM12 and BioM 148), in a completely independent test cohort of men and women psychiatric disorder participants (*n*=226), for prediction of SI state, as well as for prediction of future psychiatric hospitalizations due to suicidality ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}, [Table 3](#tbl3){ref-type="table"} and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}). We were successful in this endeavor, leading to identification of universal biomarkers that work across gender and diagnoses, such as CLN5 and AK2.

We also studied their predictive ability in participants in the independent cohort grouped by the subtypes described above, as well as grouped by a more personalized approach, by psychiatric diagnosis and gender. We then compared the universal approach to the subtypes approach and the personalized approach, and show that the subtype and personalized approaches permit enhanced precision of predictions for different biomarkers ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}, [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}, [Table 3](#tbl3){ref-type="table"} and [Supplementary Table S4](#sup1){ref-type="supplementary-material"}).

For SI prediction in the independent test cohort, CLN5, from the Bonferroni biomarkers list, a decreased in expression biomarker, had an area under the curve (AUC) of 65% (*P*=1.86E−04) across all subjects, and 75% (4.43E−03) in the low mood subtype. It also survived correction for multiple comparisons for the Step 4 testing of the 154 universal biomarkers (from the combined Top Dozen and Bonferroni lists). CLN5 also had an AUC of 87% (*P*=1.16E−02) for predicting future hospitalizations for suicidality in the first year of follow-up in male post-traumatic stress disorder. CLN5 (ceroid-lipofuscinosis, neuronal 5) is a completely novel finding. It has no prior evidence as a biomarker for suicide or for involvement in other psychiatric disorders. CLN5 is a lysosomal regulatory protein, known to date to be involved in neurodegenerative, lysosomal storage diseases.

For prediction of future hospitalizations for suicidality in the first year of follow-up in the independent test cohort, AK2, from the Bonferroni biomarkers list, a decreased in expression biomarker, had an AUC of 60% (*P*=2.31E−02) across all subjects, 68% (*P*=6.72E−03) in the combined subtype and 78% (*P*=2.70E−03) for male schizoaffectives. AK2 also had an AUC of 64% (*P*=5.39E−04) for predicting SI state across all subjects in the independent test cohort, as well as an AUC of 75% (*P*=2.93E−02) in male schizophrenia. AK2 (adenylate kinase 2) is also a completely novel finding. It has no prior evidence as a biomarker for suicide, but does have evidence for a decrease in expression in brains of schizophrenics.^[@bib11]^ AK2 is a mitochondrial gene, known to have an important role in cellular energy homeostasis and in adenine nucleotide metabolism, as well as may have a role in apoptosis.

As for examples of previously known biomarkers reproduced in this study, for SI prediction in the independent test cohort, SLC4A4, a top increased in expression biomarker, had an AUC of 64% (*P*=3.83E−04) across all subjects, 69% (6.13E−04) in the combined subtype and 77% (9.72E−04) in male bipolars. SKA2, a top decreased in expression biomarker, had an AUC of 61% (*P*=3.35E−03) across all subjects, 74% (5.91E−03) in the low mood subtype and 79% (1.35E−02) in male schizophrenics.

In addition, we used two previously described clinical instruments in the form of apps, the SASS that measures anxiety and mood, and the CFI-S that measures risk for suicide indirectly, without asking about SI.^[@bib4],\ [@bib5]^ The scores from these apps showed good predictive ability for both state (SI) and trait (future hospitalizations), in all participants ([Figure 4](#fig4){ref-type="fig"}, [Table 3](#tbl3){ref-type="table"}). There are interesting variations in different subtypes and personalized by gender and diagnosis ([Supplementary Table S4](#sup1){ref-type="supplementary-material"}), suggesting the distinctness and homogeneity of those subgroups.

We also combined a panel of the Top Dozen biomarkers with measures of anxiety and mood (SASS), and with the suicide risk scale (CFI-S), into a broad spectrum universal predictor algorithm (UP Suicide), our *a priori* endpoint as in our previous studies. The UP Suicide provides the biomarkers with mental state (SASS) and personal history context (CFI-S), enhancing precision of predictions ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Across all subjects in the independent test cohort, UP Suicide 12 had an AUC of 90% (*P*=3.87E−21) for state (SI) prediction, as well as an AUC of 77% (*P*=2.87E−08) for trait (future hospitalizations for suicidality) predictions. The results for predicting SI were even stronger in the low mood subtype (AUC of 92%, *P*=7.42E−06) and, in male bipolars, the highest risk group (AUC 96%, *P*=8.03E−08). For predicting future hospitalizations, the results were stronger in the high anxiety subtype (AUC 79%, *P*=7.52E−03) and in male depression (AUC 95%, *P*=4.88E−04).

Step 5: Biological vulnerability understanding
----------------------------------------------

### Evidence for involvement in other disorders

We conducted Convergent Functional Genomics analyses using the Top Dozen and Bonferroni biomarkers ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}), which suggest that a majority (89%) of suicide biomarkers are involved in other psychiatric disorders, providing a basis for co-morbidity and increased vulnerability. A number of biomarkers (18%) were also involved in aging and longevity, possible substrates for our 'life switch' hypothesis.

### Biological pathways

We conducted biological pathway analyses using the Bonferroni validated biomarkers, which suggest that neurotrophic factors, programmed cell death and insulin signaling are involved in the biology of suicide ([Table 4](#tbl4){ref-type="table"}).

### Networks and Interactions

We conducted STRING analyses that revealed groups of directly interacting genes, in particular HTR2 A/ARRB1/GSK3B, and SLC4A4/AHCYL1/AHCYL2 ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). These networks may have biological significance and could be targeted therapeutically.

### Circadian

A number of top biomarkers identified by us have biological roles that are related to the circadian clock ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}). To be able to ascertain all the genes in our dataset that were circadian and do estimates for enrichment, we compiled from the literature a database of all the known genes that fall into these three categories, numbering a total of 1468 genes. Using an estimate of about 21 000 genes in the human genome, that gives about 7% of genes having some circadian pattern. Out of our 154 top biomarker genes, 18 had circadian evidence (11.7%) ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}), suggesting a 1.7-fold enrichment for circadian genes. Circadian clock abnormalities are related to mood disorders^[@bib12],\ [@bib13]^ and sleep abnormalities have been implicated in suicide.^[@bib14]^

### Enrichment in suicide completers

Of the candidate biomarkers from the Prioritization step, 125/430 of the DE ones (29.1%) and 37/180 of the AP ones (20.6%) were Bonferroni validated in suicide completers. There is a 1.4-fold enrichment in DE vs AP, which suggests that completion of suicide may be due more to an incremental change in expression of genes rather than the complete turning on and off of genes.

Step 6: Therapeutics
--------------------

### Pharmacogenomics

A number of individual top biomarkers are known to be modulated by medications in current clinical use for treating suicidality, such as lithium (HTR2A, GSK3B, ITGB1BP1 and BCL2), clozapine (IL6, CD164, CD47, HTR2A, PGK1, DYRK2, IFNG and LPAR1) and omega-3 fatty acids (APOE, CD47, ACP1, GATM, LHFP and LPAR1) ([Figure 7](#fig7){ref-type="fig"}, [Table 5](#tbl5){ref-type="table"} and [Supplementary Table S5](#sup1){ref-type="supplementary-material"}). In particular, HTR2A and CRYAB are at the overlap of lithium and clozapine, and MBP is at the overlap of all three treatments ([Figure 7](#fig7){ref-type="fig"}). Omega-3 fatty acids may be a widely deployable preventive treatment, with minimal side effects, including in women who are or may become pregnant. Of note, CD109, a Bonferroni list biomarker increased in expression in suicidality in our studies ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}), has also reported to be increased in expression by treatment of lymphoblastoid cells with the SSRI paroxetine, and thus merits follow-up as a potentially useful biomarker for treatment-emergent SI.

### New drug discovery/repurposing

Bioinformatic analyses using the gene expression signature of panels of top biomarkers identified new potential therapeutics for suicidality, such as ebselen (a lithium mimetic with anti-inflammatory and antioxidant properties),^[@bib15],\ [@bib16]^ piracetam (a nootropic cyclic derivative of GABA),^[@bib17]^ chlorogenic acid (an antioxidant polyphenol from coffee)^[@bib18]^ and metformin (an antidiabetic and possible longevity promoting drug)^[@bib19]^ ([Table 6](#tbl6){ref-type="table"}).

### Phenomenology

SASS can be used to identify possible subtypes of suicidality (low mood, high anxiety, combined and non-affective) that may have practical utility, as we have shown in this work. The top CFI-S items distinguishing high SI from intermediate SI and no SI states were dissatisfaction with one's life, social isolation and lack of coping skills in the face of stress. The top CFI-S items distinguishing those that had future hospitalizations for suicidality versus those that did not were past history of suicidality, command auditory hallucinations and social isolation ([Figure 4](#fig4){ref-type="fig"}). This provides empirical evidence that, in general, reducing social isolation is a good behavioral therapeutic intervention for preventing suicidality. In different individuals different CFI-S items are positive, providing avenues for tailored and targeted (psycho)therapeutic interventions.

Final summation: overall evidence for establishment of clinical utility
-----------------------------------------------------------------------

For the universal biomarkers identified by us, combining all the available evidence from this current work and the published literature, into a convergent functional evidence score, brings to the fore biomarkers that might have clinical utility, for future studies in the field ([Figures 8](#fig8){ref-type="fig"}, [9](#fig9){ref-type="fig"}, and [Supplementary Table S7](#sup1){ref-type="supplementary-material"}).

Studies in male bipolars: personalization versus universal
----------------------------------------------------------

As a comparator to the universal approach across gender and diagnoses, we also conducted within-participant longitudinal biomarker discovery analyses in male bipolars only, the largest subgroup (*n*=20 participants, 65 testing visits) in our discovery cohort. Male bipolars are the highest risk group for suicide clinically and have been the focus of earlier suicide biomarker studies by us, with an *N* (*n*=9) that was less than half of the current one. The discovery step was followed by prioritization and by validation in male suicide completers. We reproduced and expanded some of our previous biomarker findings in bipolar disorder ([Table 2B](#tbl2){ref-type="table"}, [Figure 3](#fig3){ref-type="fig"} and [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}). We tested the male bipolar derived top dozen biomarkers ([Table 2B](#tbl2){ref-type="table"}) and all the biomarkers that survived Bonferroni correction after the validation step ([Supplementary Table S8](#sup1){ref-type="supplementary-material"}), for prediction of SI and for prediction of future psychiatric hospitalizations due to suicidality in the male bipolar subgroup (*n*=49) in the independent test cohort ([Figure 3](#fig3){ref-type="fig"} and [Supplementary Table S10](#sup1){ref-type="supplementary-material"}). We were successful in the identification of predictive biomarkers that might be more specific for suicidality in male bipolars. We also examined whether biomarkers discovered using just male bipolar subjects yields even better predictors for male bipolar subjects than using the universal biomarkers and found that to be the case for trait (hospitalizations) predictions ([Figure 3](#fig3){ref-type="fig"}). A number of top male bipolar biomarkers identified by us are targets of medications in current clinical use for treating suicidality ([Supplementary Table S12](#sup1){ref-type="supplementary-material"}). Bioinformatic drug repurposing analyses using the gene expression biosignature of panels of top biomarkers identified new potential therapeutics for suicidality in male bipolars ([Table 6C and D](#tbl6){ref-type="table"}). The top compounds identified include betulin (a natural plant compound with longevity and anticancer properties), naproxen (a non-steroidal anti-inflammatory), as well as chlorphenesin and baclofen (central nervous system acting muscle relaxants used to treat pain and spasms). Combining all the available evidence from this current work and the published literature, into a convergent functional evidence score ([Figure 10](#fig10){ref-type="fig"} and [Supplementary Table S13](#sup1){ref-type="supplementary-material"}), leads to a prioritization of biomarkers for future studies in the field.

Discussion
==========

Was our quest for more universal predictors or our quest for more personalized predictors more informative? The answer seems to be both, for different and complementary reasons. The universal approach may illuminate a more specific core biology for suicide, the personalized approach by gender and diagnosis may provide a more sensitive and context dependent applicability. The new subtypes we identified seem to have some utility ([Figure 2](#fig2){ref-type="fig"} and [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). They merit future exploration and are easy to assess in the general population using our SASS questionnaire/app.

The current work is more comprehensive in design and larger in size than our previous studies.^[@bib4],\ [@bib5],\ [@bib7]^ We used a systematic discovery, prioritization, validation, and testing approach.^[@bib2]^ For discovery, we used a hard to accomplish but powerful within-participant design, with an *N* of 66 participants with 193 visits. A within-participant design factors out genetic variability, as well as some medications, lifestyle and demographic effects on gene expression, permitting identification of relevant signal with *N* as small as 1.^[@bib6]^ Another benefit of a within-participant design may be accuracy/consistency of self-report of psychiatric symptoms ('phene expression'), similar in rationale to the signal detection benefits it provides in gene expression. Just the male bipolar sub-component alone had twice as many participants in discovery (20 vs 9) and four times as many participants in validation (38 vs 9) than our original breakthrough study on suicide biomarkers in male bipolars published in 2013.^[@bib7]^ Out of the six Bonferroni-validated biomarkers in that study,^[@bib7]^ four were also Bonferroni validated in the current study (SAT1, BF114768/UBA6, MARCKS and PTEN), at the exact same probe sets. Moreover, LHFP, a biomarker that just missed the Bonferroni cutoff in the original male bipolar work,^[@bib7]^ is a universal Bonferroni validated biomarker in the current work, with predictive ability for SI state in the high anxiety subtype (AUC of 78%, *P*-value 1.95E−02), female bipolars (AUC of 79%, *P*-value 4.6E−02) and male depression (AUC 69%, *P*-value 3.32E−02), as well as very strong predictive ability for future hospitalizations for suicidality in male depression (AUC 98%, *P*-value 2.54E−04) ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). LHFP (lipoma HMGIC fusion partner), increased in expression in blood in our studies, is also previously reported to be increased in expression in brains of suicide completers.^[@bib20]^ Of note, SAT1, which is increased in expression in suicide in our studies, degrades spermidine, a compound recently implicated in longevity.^[@bib21]^ This is consistent with our overall 'life switch'^[@bib22]^ hypothesis.

Our Bayesian-like Convergent Functional Genomics platform used for prioritizing findings following the discovery step ensures robust built in reproducibility, as it is based on corroborating evidence by other groups, using different methodologies and cohorts. No single approach or study is perfect and datasets are especially powerful in combination.

The phenotypic measures apps scores by themselves ('digital biomarkers') were more precise predictors than the blood biomarkers by themselves, although their combination did show some synergy ([Table 3](#tbl3){ref-type="table"}). However, blood biomarkers may have usefulness for objective diagnostic testing and patient stratification, over and above clinical classifications. This may be particularly important when individuals choose not to share how they feel and do not seek help. We observed such possible discrepancies for different subtypes and gender/diagnostic groups ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

In terms of how our biomarker discoveries might be applied in clinical laboratory settings, we suggest that one might combine the best universal biomarkers with the best personalized biomarkers, to have the best of both worlds. In practice, every new patient tested would be normalized against the database of similar patients already tested and compared with them for ranking and risk prediction purposes, regardless of whether a platform such as Affymetrix or a more targeted one is used in the end clinically. As databases get larger, normative population levels can and should be established, similar to any other laboratory measures. Moreover, longitudinal monitoring of changes in biomarkers within an individual, measuring most recent slope of change, maximum levels attained and maximum slope of change attained, may be even more informative than simple cross-sectional comparisons of levels within an individual with normative populational levels and is the focus of future studies by our group.

Biomarkers may also be useful for patient stratification and measuring response to treatment (pharmacogenomics) ([Figure 7](#fig7){ref-type="fig"}, [Table 5](#tbl5){ref-type="table"} and [Supplementary Table S5](#sup1){ref-type="supplementary-material"}), and drug discovery/repurposing ([Table 6](#tbl6){ref-type="table"}). In terms of therapeutics, ebselen, although discovered decades ago for other indications and shown to be safe and well tolerated in human studies, has been recently proposed as a treatment for bipolar disorder.^[@bib15]^ The fact that it was the compound that had the strongest/perfect score on the Connectivity Map analyses as having the opposite gene expression effects to the biosignature of the Top Dozen universal biomarkers for suicidality is a tantalizing result. Piracetam and chlorogenic acid are compounds that can be classified as nutraceuticals, already in use and relatively safe and innocuous, which may facilitate adoption, along with omega-3 fatty acids, for pre-emptive population-level approaches. Metformin, besides being originally an antidiabetic compound, may act on promoting longevity by mimicking the effects of calorie restriction. The fact that it may have anti-suicidal properties is consistent with a possible suicide/longevity 'life switch' machinery, as previously proposed by us.^[@bib22]^ Interestingly, clozapine and fluoxetine, two known medications used to treat suicidality, were identified by our bioinformatics approach, but with lower priority than metformin ([Table 6B](#tbl6){ref-type="table"}). They serve as reassuring positive controls.

The biomarkers also provide a window toward a more nuanced understanding of the biology of suicide. The universal biomarkers may be pointing to a core common biology, such as inflammation and stress response, and the balance between neuronal cell survival and apoptosis, that is, a cellular level 'life switch'. The personalized biomarkers (such as male bipolar biomarkers), may be more reflective of the psychiatric co-morbidity driving suicidality and medication effects in different gender/diagnostic groups, such as mTOR signaling in male bipolars, which is modulated by mood regulating drugs, including a new one (ketamine),^[@bib23]^ which also shows promise for treating suicidality.^[@bib24]^

Among the Top Dozen universal biomarkers ([Table 2A](#tbl2){ref-type="table"}) was HTR2A, which was increased in expression and is targeted by most modern antipsychotics, and ARRB1, which was decreased in expression and is downstream of HTR2A in the signaling cascade, and also interacts with GSK3B,^[@bib25]^ which was decreased in expression as well ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). The combination of these expression effects may provide for excessive/unbridled signaling^[@bib26]^ as a key pathological step in suicidality. For male bipolars, similar STRING analysis revealed a network centered on PTK2 ([Supplementary Figure S4](#sup1){ref-type="supplementary-material"}).

Finally, a *post-hoc* convergent functional evidence score of the totality of evidence in these series of studies, including testing for predictive ability, evidence for biological predisposition/involvement in psychiatric disorders, and for being potential drug targets, identifies APOE and IL6 as the top overall biomarkers of interest, pointing to stress, inflammation and accelerated aging ([Figure 9](#fig9){ref-type="fig"} and [Supplementary Table S7](#sup1){ref-type="supplementary-material"}). It is unclear at this point whether they are just markers of that co-occurring pathology or are direct drivers of suicide as well.

Overall, we believe this work is a major step forward towards understanding, diagnosing and treating suicidality. Suicide occurs maladaptively in the face of negative life events, with the individual who commits suicide being vulnerable due to a psychiatric illness and addictions, misperceiving circumstances and/or overreacting in an impulsive manner. Related to that, suicide can be an attempt to assuage perceived guilt or an attempt to harm (through social opprobrium or guilt) the individual(s) perceived to be the source of the suffering and lack of success of the suicidal person. Conversely, a well-balanced and functioning mind is protective. To predict behaviors, it may be important to provide context to the biomarkers, as to how the person feels (SASS) and who the person is (CFI-S) ([Figure 5a](#fig5){ref-type="fig"}). That is why the combined UP-Suicide predictor is robust across all subjects, in subtypes and personalized by gender and diagnosis, with AUCs over 90% ([Figure 6](#fig6){ref-type="fig"}). We hope that our risk assessment tools may become self-cancelling predictions once tested and deployed in the general population, as they can lead to precision prevention with early targeted interventions: biological, psychological and social. Indeed, beyond biological markers and drug treatments, SASS can help identify different subtypes and in different individuals different CFI-S items are positive, providing avenues for tailored and targeted (psycho)therapeutic interventions. Culture may have a particularly important role ([Figure 5a](#fig5){ref-type="fig"}). Negative behaviors in the past, negative examples from the environment and negative cultural values can lead to a downward spiral of failure. Reversing negative cultural influences on behaviors involves coming to terms with or forgetting the past, starting to accumulate positive precedents, changing the environment (or moving to a different environment) and gravitating to/adopting a different set of cultural values. Given that one person dies from suicide every 40 seconds worldwide, the importance and urgency of efforts such as ours cannot be overstated.^[@bib27]^ We demonstrate how this field can develop precision, move towards personalization, and have tools to pre-empt suicide acutely, as well as prevent suicide in the long term. We envision the participation of individuals at risk in such efforts initially, followed by the pervasive deployment of the tools in society at large in the long term. It has not escaped our attention that, if our 'life switch' hypothesis between suicide and longevity is correct,^[@bib22]^ the possibility exists to transform a negative into a positive.
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![Steps 1--3: discovery, prioritization and validation. (**a**) Cohorts used in study, depicting flow of discovery, prioritization and validation of biomarkers from each step. (**b**) Discovery cohort longitudinal within-participant analysis. Phchp\#\#\# is study ID for each participant. V\# denotes visit number (1, 2, 3, 4, 5 or 6). (**c**) Discovery of possible subtypes of suicidality based on high suicidal ideation (SI) visits in the discovery cohort. Participants were clustered using measures of mood and anxiety (Simplified Affective State Scale (SASS)), as well as psychosis (PANSS Positive) (**d**) Differential gene expression in the Discovery cohort, number of genes identified with DE and AP methods with an internal score of 1 and above. Red, increased in expression in high SI. Blue, decreased in expression in high SI. At the discovery step probesets are identified based on their score for tracking SI with a maximum of internal points of 4 (33% (1 pt), 50% (2 pt) and 80% (4 pt)). (**e**) Prioritization with Convergent Functional Genomics (CFG) for prior evidence of involvement in suicide. In the prioritization step probesets are converted to their associated genes using Affymetrix annotation and GeneCards. Genes are prioritized and scored using CFG for Suicide evidence with a maximum of eight external points. Genes scoring at least 4 points out of a maximum possible of 12 points total internal and external score are carried to the validation step. (**f**) Validation in an independent suicide completers cohort from the coroner's office. In the validation step biomarkers are assessed for stepwise change from the discovery groups of participants with no SI, to high SI, to suicide completion, using analysis of variance. Stringent Bonferroni correction is calculated for the total number of probesets analyzed.](mp2017128f1){#fig1}

![Step 4: Testing for Diagnostics. Best single universal biomarkers predictors. From Top Dozen List (bold) and from Bonferroni List (combined 154 biomarkers). Bar graph shows best predictive biomarkers in each group. \*Nominally significant *P*\<0.05. \*\*Survives correction for multiple comparisons testing of 154 biomarkers, *P*\<0.000325. Table underneath the figures displays the actual number of biomarkers for each group whose region of interest (ROC) area under the curve (AUC) *P*-values are at least nominally significant. Some female diagnostic groups are missing from the graph, as they did not have any nominally significant biomarkers, due at least in part to the small number of cases.](mp2017128f2){#fig2}

![Step 4: Testing for Diagnostics. Universal and male bipolar biomarkers. Best individual biomarkers from Top Dozen List and from Bonferroni List, for universal and for male bipolar. We only show biomarker results where region of interest (ROC) area under the curve (AUC) *P*-values are at least nominally significant and AUCs are at least 0.6 (60%). (**a**) Circos plot depicting the best individual biomarker predictions for suicidal ideation (SI) state in the independent cohort (across all participants, in subtypes and personalized by gender and diagnosis), using universal biomarkers. (**b**) Circos plot depicting the best individual biomarker predictions for future hospitalizations for suicidality in the first year following testing in the independent cohort (across all participants, in subtypes and personalized by gender and diagnosis), using universal biomarkers. (**c**) Circos plot depicting the best individual biomarker predictions for SI state in the independent male bipolar sub-cohort, using universal biomarkers and male bipolar biomarkers. (**d**) Circos plot depicting the best individual biomarker predictions for future hospitalizations for suicidality in the first year following testing in the independent male bipolar sub-cohort, using universal biomarkers and male bipolar biomarkers. The circumference bands represent and are proportional to the number of participants in each cohort. The ribbons represent and are proportional to the AUC of the predictions. Table underneath the figures displays the actual numerical results.](mp2017128f3){#fig3}

![Convergent Functional Information for Suicide (CFI-S) testing. Testing in a large cohort that combines the discovery and test cohorts used for biomarker work. CFI-S was developed independently of any data from this study, by compiling known socio-demographic and clinical risk factors for suicide. It is composed of 22 items that assess the influence of mental health factors, as well as of life satisfaction, physical health, environmental stress, addictions and cultural factors known to influence suicidal behavior, as well as two demographic factors, age and gender. (**a**) Prediction of high suicidal ideation (HAMD SI\>=2). (**b**) Prediction of future hospitalizations due to suicidality within one year of follow-up. Table under **a** depicts individual items and their ability to differentiate between participants with No SI, Intermediate SI and High SI. Stepwise refers to gradual increase between the three groups (No SI, Intermediate SI, High SI). Table under **b** depicts individual items and their ability to differentiate between participants with and without future hospitalizations due to suicidality. Different items are positive in different individuals, providing leads for targeted (psycho)therapeutic interventions.](mp2017128f4){#fig4}

![Predicting suicidality using a broad-spectrum predictor (UP-Suicide), which is an algorithm combining phenotypic information measures (Convergent Functional Information for Suicide (CFI-S) and Simplified Affective State Scale (SASS) (anxiety and mood)) and a panel of the Top Dozen universal biomarkers (BioM 12). (**a**) Model of various factors involved in suicidality (environmental stressors, life failures, body health issues, mind frailty, addiction problems and cultural examples). CFI-S, SASS and Biomarker panel are the components of our UP-Suicide. SA, suicide attempt; SI, suicidal ideation. (**b**) UP-Suicide predictions in the independent testing cohort, for High SI and for future hospitalizations for suicidality in the first year. (**c**) A dimensional view of risk stratification using phenotypic information measures and example of two high-risk participants. We calculated Euclidian distances from origin. Participant phchp158 is a divorced African American male in his late 20s with a long history of schizoaffective disorder, bipolar type and cannabis abuse. He was tested by us once (v1), while he was hospitalized for a suicide attempt by hanging. In the 5 years following testing, he has had two additional hospitalizations for suicidality: one for SI and one for attempt by overdose. He has had two hospitalizations for psychosis exacerbation without suicidality during this time span as well. Moved out of state, lost to follow-up since December 2015. Participant phchp328 was a divorced Caucasian female in her late 30s with a long history of depression, post-traumatic stress disorder (PTSD), borderline personality disorder and polysubstance abuse/dependence. She was first tested by us (v1) while inpatient for SI. Over the next year she subsequently had six psychiatric hospitalizations for suicidality: five due to SI and one due to a suicidal attempt by overdose. She also had one hospitalization for opioid withdrawal and depression during this time span as well. She committed suicide by overdose with pills, leaving behind a suicide note addressed to her mother. Her UP-Suicide score at Visit 1, composed of the panel of top dozen biomarkers (BioM12) scores and phenomic measures scores (CFI-S and SASS), was at the 100% of the scores of all the psychiatric participants visits in the current study. That testing was conducted during an inpatient hospitalization due to SI. Although her scores did improve at subsequent outpatient testing visits (Visits 2 and 3), this high watermark score indicated her high risk. After the last testing visit in our study, she had four subsequent psychiatric hospitalizations: three due to SI and one for opioid withdrawal/detox (the last one, which ended 2 weeks before the date of her committing suicide (T)).](mp2017128f5){#fig5}

![UP-Suicide across all, by subtypes and personalized by gender/diagnosis. UP-Suicide composed of the panel of the Top Dozen universal biomarkers (BioM 12), Convergent Functional Information for Suicide (CFI-S) and Simplified Affective State Scale (SASS) (anxiety and mood). Plot depicts area under the curve (AUC) for the UP-Suicide predicting suicidal ideation (SI) and hospitalizations within the first year in all participants, as well as separately in subtypes, and by gender and diagnosis (Gender/Dx). Two asterisks indicate the comparison survived Bonferroni correction for all the multiple comparisons depicted. A single asterisk indicates nominal significance of *P*\<0.05. Bold outline indicates that the UP-Suicide was synergistic to its components, that is, performed better than the gene expression biomarkers or phenomic measures individually. Table contains descriptive statistics for all participants together, as well as separately by subtypes and by gender/dx. For female gender/dx groups, only the female bipolar subgroup had enough participants to yield at least a nominally significant AUC. Bold indicates the measure survived very stringent Bonferroni correction for all the multiple comparisons in our whole study (2737 biomarkers and phenes, resulting in a Bonferroni cutoff of 1.83E−05). We also show Pearson's correlation data in the SI test cohort for HAMD-SI vs UP-Suicide, as well as Pearson's correlation data in the hospitalization test cohort for frequency of hospitalizations for suicidality in the first year and for frequency of hospitalizations for suicidality in all future available follow-up interval (which varies among participants, from 0.40 to 10.42 years).](mp2017128f6){#fig6}

![Step 6: Therapeutics. Pharmacogenomics. Individual biomarkers modulated by medications used in the treatment of suicidality. Universal biomarkers, bold; male bipolar, italic; both, bold and italic and underlined. Red, increased in expression in suicidality. Blue, decreased in expression in suicidality.](mp2017128f7){#fig7}

![Convergent functional evidence---multiple steps for identification and establishment of clinically utility of biomarkers.](mp2017128f8){#fig8}

![Universal biomarkers---convergent functional evidence (CFE) for involvement in suicidality. Top Dozen and Bonferroni biomarkers. *Post-hoc* summation of all the evidence form discovery, validation, prioritization and testing (for state---SI and for trait-future hospitalizations), along with evidence for involvement in other psychiatric disorders and for being a target of drugs. This prioritization highlights for future studies biomarkers that may have broad applicability in the field, for diagnostics and therapeutics. ASD, autism spectrum disorder; BP, bipolar; MDD, major depressive disorder; PTSD, post-traumatic stress disorder; SZ, schizophrenia.](mp2017128f9){#fig9}

![Male bipolar biomarkers---convergent functional evidence for involvement in suicidality. Top Dozen and Bonferroni biomarkers. *Post-hoc* summation of all the evidence form discovery, validation, prioritization and testing, along with evidence for involvement in other psychiatric disorders and for being a target of drugs. This prioritization highlights for future studies biomarkers that may have broad applicability in the field, for diagnostics and therapeutics. ASD, autism spectrum disorder; BP, bipolar; MDD, major depressive disorder; PTSD, post-traumatic stress disorder; SZ, schizophrenia.](mp2017128f10){#fig10}

###### Demographics

  *A. Universal*                                                                                                          *Participants*   *Gender*             *Diagnosis*                                              *Ethnicity*                               *Age mean (s.d.)*
  ----------------------------------------------------------------------------------------------------------------------- ---------------- -------------------- -------------------------------------------------------- ----------------------------------------- ------------------------------------------------------------------
  *Discovery*                                                                                                                                                                                                                                                      
   Discovery cohort (longitudinal within-participant changes in SI)                                                       66               Male=49 Female=17    BP=25 MDD=17 SZA=9 SZ=4 PTSD=8 MOOD=2 PSYCH=1            EA=51 AA=14 Asian=1                       47.94 (9.47)
                                                                                                                                                                                                                                                                    
  *Validation*                                                                                                                                                                                                                                                     
   Independent validation cohort for gene expression (suicide completers)                                                 45               Male=38 Female=7     NP=19 MDD=19 BP=2 SZ=1 AX=1 Alcoholism=1 ADHD=1 PTSD=1   EA=37 AA=7 Hispanic=1                     40.69 (16.93)
                                                                                                                                                                                                                                                                    
  *Testing*                                                                                                                                                                                                                                                        
   All                                                                                                                                                                                                                                                              
    Independent testing cohort for predicting state (SI at time of assessment)                                            226              Male=184 Female=42   BP=68 MDD=32 SZA=53 SZ=45 PTSD=19 MOOD=5 PSYCH=4         EA=148 AA=73 Asian=1 Hispanic=3 Mixed=1   All=50.26 (9.47) No SI=51.1 Intermediate SI=49 High SI=44.3
    Independent testing cohort for predicting trait (hospitalizations for suicidality in the year following assessment)   194              Male=170 Female=24   BP=52 MDD=30 SZA=45 SZ=43 PTSD=16 MOOD=5 PSYCH=3         EA=126 AA=64 Hispanic=3 Mixed=1           All=50.65 (9.14) No Hosp for SI=50.91 Hosp for SI=47.66
   Subtypes                                                                                                                                                                                                                                                         
    High anxiety subtype                                                                                                  46               Male=40 Female=6     BP=13 MDD=10 SZA=9 SZ=11 PTSD=2 MOOD=1                   EA=27 AA=19                               All=50.96 (7.63) No SI=52.1 Intermediate SI=52.5 High SI=39.4
    Low mood subtype                                                                                                      76               Male=57 Female=19    BP=21 MDD=17 SZA=15 SZ=15 PTSD=6 MOOD=1 PSYCH=1          EA=53 AA=20 Hispanic=2 Asian=1            All=51.53 (10.04) No SI=51.44 Intermediate SI=51.81 High SI=51.9
    Combined subtype                                                                                                      86               Male=61 Female=25    BP=30 MDD=11 SZA=21 SZ=11 PTSD=11 MOOD=2                 EA=63 AA=21 Hispanic=1 Mixed=1            All=47.95 (9.36) No SI=50.79 Intermediate SI=45.43 High SI=43.06
    Non-affective (psychotic) subtype                                                                                     141              Male=121 Female=20   BP=40 MDD=17 SZA=35 SZ=32 PTSD=10 MOOD=4 PSYCH=3         EA=86 AA=52 Hispanic=2 Mixed=1            All=50.71 (9.49) No SI=50.89 Intermediate SI=51.67 High SI=42.33

  *B. Male bipolar*                                                                                                                   *Participants*   *Gender*   *Diagnosis*                                *Ethnicity*             *Age mean (s.d.)*
  ----------------------------------------------------------------------------------------------------------------------------------- ---------------- ---------- ------------------------------------------ ----------------------- -------------------------------------------------------------------
  *Discovery*                                                                                                                                                                                                                        
   Male bipolar discovery cohort (within-participant changes in SI)                                                                   20               Male=20    BP=20                                      EA=20                   48.12 (9.10)
                                                                                                                                                                                                                                      
  *Validation*                                                                                                                                                                                                                       
   Male independent validation cohort for gene expression (suicide completers)                                                        38               Male=38    NP=18 MDD=16 BP=1 SZ=1 AX=1 Alcoholism=1   EA=31 AA=6 Hispanic=1   40.82 (17.31)
                                                                                                                                                                                                                                      
  *Testing*                                                                                                                                                                                                                          
   Male bipolar independent testing cohort for predicting state (SI at time of assessment)                                            49               Male=49    BP=49                                      EA=43 AA=5 Hispanic=1   All=49.16 (10.01) No SI=50.19 Intermediate SI=48.73 High SI=40.42
   Male bipolar independent testing cohort for predicting trait (hospitalizations for suicidality in the year following assessment)   44               Male=44    BP=44                                      EA=39 AA=4 Hispanic=1   All=48.88 (10.23) No Hosp for SI=48.76 Hosp for SI=52.25

Abbreviations: AA, African Amercian; ADHD, attention deficit disorder; AX, anxiety disorder; BP, bipolar; EA, European-American; MDD, major depressive disorder; MOOD, mood disorder not otherwise specified; NP, non-psychiatric; PSYCH, psychosis not otherwise specified; PTSD, post-traumatic stress disorder; SZA, schizoaffective disorder; SZ, schizophrenia.

###### The Top Dozen list of candidate biomarker genes - evidence for involvement in suicidality

  *A. Top Dozen biomarkers from universal approach*                                                                                                                                                                                                                                                                                                                                                                                 
  -------------------------------------------------------------------------------------- -------------- ----------------- ------------------------------------------------------------------------------ --------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- ---- ------------- --------------------------------------
  *Top biomarkers from discovery---step 1*                                                                                                                                                                                                                                                                                                                                                                                          
   *HIST1H2BO*  Histone cluster 1, H2bo                                                  214540_at         \(I\) DE/4                                                                                                                                                                Our previous work in males (I)(214540_at) Blood^[@bib4]^                                                                    4    5.37E−14      Top discovery DE increased gene
  ** ***ERG*   V-ets avian erythroblastosis virus E26 oncogene homolog                   213541_s\_at      \(D\) DE/4                                                                                                                                                                Our previous work in males (D)(213541_s\_at) Blood^[@bib4]^ Our previous work in females (D)(213541_s\_at) Blood^[@bib5]^   4    NS            Top discovery DE decreased gene
  ** ***GAB1*   GRB2-associated binding protein 1                                        242572_at         \(I\) AP/4                                                                                                                                                                Our previous work in males (I)(242572_at) Blood^[@bib4]^                                                                    4    NS            Top discovery AP increased gene
  ** ***CCL28*   Chemokine (C--C motif) ligand 28                                        224240_s\_at      \(D\) AP/4                                                                                                                                                                Our previous work in males (D)(224240_s\_at) Blood^[@bib4]^ Our previous work in females (D)(224240_s\_at) Blood^[@bib5]^   4    NS            Top discovery AP Decreased gene
                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Top biomarkers from prioritization---step 2*                                                                                                                                                                                                                                                                                                                                                                                     
  ** ***HTR2A*   5-Hydroxytryptamine (serotonin) receptor 2A, G protein-coupled          244130_at         \(I\) DE/2     Association^[@bib28],\ [@bib29],\ [@bib30],\ [@bib31],\ [@bib32],\ [@bib33]^   \(I\) Prefrontal cortex^[@bib34]^ (I) Frontal cortex^[@bib35],\ [@bib36]^   \(D\) Platelets^[@bib37]^ Our previous work in females (D) (244130_at) Blood^[@bib5]^                                       10   NS            Top prioritization DE increased gene
  ** ***SKA2*   Spindle and kinetochore-associated complex subunit 2                     225686_at       (D)DE/1 (D)AP/1  Association^[@bib38]^                                                          \(D\) Prefrontal cortex^[@bib38]^                                           (D)Blood^[@bib38]^ (D)Blood, saliva^[@bib39]^ Our previous work in males (D)(225686_at) Blood^[@bib4]^                      9    *0.0045542*   Top prioritization DE decreased gene
  ** ***SLC4A4*   Solute carrier family 4 (sodium bicarbonate cotransporter), member 4   210739_x\_at      \(I\) AP/1     Association^[@bib40]^                                                          \(D\) Prefrontal cortex(BA 46/10)^[@bib41]^                                 Our previous work in males (I)(210739_x\_at) Blood^[@bib4]^                                                                 7    7.74E−05      Top prioritization AP increased gene
  ** ***IFNG*   Interferon, gamma                                                        210354_at         \(D\) AP/1     Association^[@bib42]^                                                          \(D\) Hippocampus^[@bib43]^                                                 \(D\) Blood^[@bib44]^ Our previous work in females (D)(210354_at) Blood^[@bib5]^                                            9    NS            Top prioritization AP decreased gene
                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Top biomarkers from validation---step 3*                                                                                                                                                                                                                                                                                                                                                                                         
  ** ***PSME4*   Proteasome activator subunit 4                                          237180_at         \(I\) DE/1                                                                                    \(I\) Anterior cingulate cortex^[@bib20]^                                                                                                                                                               5    2.64E−36      Top validation DE increased gene
  ** ***LDLRAP1*   Low-density lipoprotein receptor adaptor protein 1                    57082_at          \(D\) DE/1                                                                                    \(I\) Anterior cingulate cortex^[@bib20]^                                   Our previous work in males (D)(221790_s\_at) Blood^[@bib4]^                                                                 5    1.48E−38      Top validation DE decreased gene
  ** ***PPAP2B*   Phosphatidic acid phosphatase type 2B                                  212226_s\_at        (I)AP/1                                                                                     \(D\) Prefrontal cortex (BA 46/10)^[@bib41]^                                Our previous work in females (I)(212226_s\_at) Blood^[@bib5]^                                                               5    2.76E−17      Top validation AP increased gene
  ** ***ARRB1*   Arrestin, beta 1                                                        218832_x\_at      \(D\) AP/1                                                                                    \(D\) Prefrontal cortex (BA8/9)^[@bib45]^                                                                                                                                                               5    5.26E−17      Top validation AP decreased gene

  *B. Top Dozen biomarkers from male bipolars*                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  ------------------------------------------------------------------------------------ -------------- ------------ ------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------- ------------ --------------------------------------
  *Top biomarkers from discovery---step 1*                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ** ***BE674182*                                                                      237259_at       \(I\) DE/4                                                                                                                                                                                                                                                                                                                                                                               4.00    NS           Top discovery DE increased gene
  ** ***ICAM4*   Intercellular adhesion molecule 4 (Landsteiner--Wiener blood group)   207194_s\_at    \(D\) DE/4                                                                                                                                                                                                                                                 Our previous work in males (D) (207194_s\_at) Blood^[@bib4]^ Our previous work in females (I) (207194_s\_at) Blood^[@bib5]^   4.00    3.81E−08     Top discovery DE decreased gene
  ** ***CACNA1I*   Calcium channel, voltage-dependent, T type, alpha 1I subunit        208299_at       \(I\) AP/4                                                                                                                                                                                                                                                 Our previous work in males (I) (208299_at) Blood^[@bib4]^                                                                     4.00    NS           Top discovery AP increased gene
  ** ***ADAL*   Adenosine deaminase-like                                               239711_at       \(D\) AP/4                                                                                                                                                                                                                                                 Our previous work in males (D) (239711_at) Blood^[@bib4]^ Our previous work in females (D) (239711_at) Blood^[@bib5]^         4.00    4.53E−08     Top discovery AP decreased gene
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  *Top biomarkers from prioritization---step 2*                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ** ***HTR2A*   5-Hydroxytryptamine (serotonin) receptor 2A, G protein-coupled        244130_at       \(I\) DE/2  Association ^[@bib29],\ [@bib30],\ [@bib31],\ [@bib32],\ [@bib33],\ [@bib46]^   \(I\) Prefrontal cortex^[@bib34]^ Frontal cortex^[@bib35],\ [@bib36]^                                                                                                                                                                                                                        10.00   NS           Top prioritization DE Increased Gene
  ** ***CRHR1*   Corticotropin-releasing hormone receptor 1                            214619_at       \(D\) DE/1  Association^[@bib47],\ [@bib48],\ [@bib49]^                                     \(I\) Pituitary^[@bib50]^                                                                                                                                                                                                                                                                    7.00    NS           Top prioritization DE decreased gene
  ** ***KSR1*   Kinase suppressor of ras 1                                             213769_at       \(I\) AP/4                                                                                  \(I\) Nucleus accumbens^[@bib20]^                                                                                                                              Our previous work in males (I) (213769_at) Blood^[@bib4]^                                                                     8.00    NS           Top Prioritization AP increased gene
  ** ***CLYBL*   Citrate lyase beta like                                               239683_at       \(D\) AP/4                                                                                  \(I\) Brain^[@bib51]^                                                                                                                                          Our previous work in males (D) (239683_at) Blood^[@bib4]^                                                                     8.00    *0.008799*   Top prioritization AP decreased gene
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  *Top biomarkers from validation---step 3*                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ** ***C20orf27*   Chromosome 20 open reading frame 27                                218081_at       \(D\) DE/2                                                                                  \(I\) Anterior Cingulate Cortex^[@bib20]^                                                                                                                      Our previous work in males (D) (218081_a) Blood^[@bib4]^                                                                      6.00    1.09E−34     Top validation DE decreased gene
  ** ***SAT1*   Spermidine/spermine N1-acetyltransferase 1                             213988_s\_at    \(I\) DE/2  Association^[@bib52],\ [@bib53]^                                                \(I\) Prefrontal cortex (BA46)^[@bib54]^ (D) Prefrontal cortex^[@bib55]^ Prefrontal cortex (BA4, BA8/9, and BA11)^[@bib56]^ (BA44)^[@bib54]^ (BA9)^[@bib57]^   Our previous work in males (I) (213988_s\_at)Blood^[@bib4]^                                                                   8.00    4.06E−34     Top validation DE increased gene
  ** ***SPTBN1*   Spectrin, beta, non-erythrocytic 1                                   215918_s\_at    \(I\) AP/1                                                                                  \(I\) Nucleus accumbens^[@bib20]^                                                                                                                              Our previous work in females (I)(214856_at)Blood^[@bib5]^                                                                     5.00    6.7E−32      Top validation AP increased gene
  ** ***POLR2D*   Polymerase (RNA) II (DNA directed) polypeptide D                     214144_at       \(D\) AP/1                                                                                  \(I\) Anterior cingulate cortex^[@bib20]^                                                                                                                      Our previous work in males (D)(214144_a)Blood^[@bib4]^ Our previous work in females (I) (214144_at)Blood^[@bib5]^             5.00    2.1E−08      Top validation AP decreased gene

Abbreviations: ANOVA, analysis of variance; AP, absent/present; DE, differential expression; NS, non-stepwise in validation.

Italic *P*-values are nominally but not Bonferroni significant.

###### Step 4: Diagnostics

  *A. SI state*                                                                                                                      
  -------------------------------------------------------------- -------- ---------- --------------------------- ------------------- --------------
  *Universal*                                                                                                                        
  ** Best Biomarkers**                                                                                                                      
  **  **[SLC4A4]{.ul}                                            All        52/544          0.64/3.83E−04           0.13/1.54E−03       1.50E−03
  **  **CLN5                                                     All        52/544      **0.65/1.86E**−**04**      −0.11/6.13E−03       3.90E−04
  **  **BioM 148 Panel (Bonferroni List)                         All        52/544          0.61/6.18E−03          0.069/5.33E−02       1.77E−02
  **  **BioM 12 Panel (Top Dozen List)                           All        52/544          0.61/3.66E−03           0.12/3.02E−03       3.08E−03
  **  **BioM 2 Panel (SLC4A4 and CLN5)                           All        52/544      **0.66/4.92E**−**05**       0.14/7.82E−04       1.90E−04
  ** Phenes**                                                                                                                               
  **  **Mood                                                     All        52/544      **0.77/5.93E**−**11**      −0.38/3.17E−20       1.95E−10
  **  **Anxiety                                                  All        52/544      **0.77/3.43E**−**11**       0.31/8.60E−14      2.03E--12
  **  **Mood and Anxiety (SASS)                                  All        52/544      **0.81/5.55E**−**14**       0.40/3.66E−22       3.57E−14
  **  **CFI-S                                                    All        52/523      **0.86/9.98E**−**18**       0.43/1.03E−24       5.46E−16
  **  **Mood and Anxiety and CFI-S                               All        52/523      **0.89/2.59E**−**20**       0.49/1.60E−33       1.08E−18
  ** Phenes and Biomarkers**                                                                                                                
  **  **Mood and Anxiety and CFI-S and BioM 148                  All        52/523      **0.89/1.36E**−**20**       0.49/2.84E−33       2.88E−18
  **  ***Mood and Anxiety, and CFI-S and BioM 12 (UP-Suicide)*   *All*     *52/523*   ***0.90/3.87E***−***21***    *0.50/5.91-35*     *3.42E*−*19*
  **  **Mood and Anxiety, and CFI-S and BioM2                    All        52/523      **0.89/4.56E**−**21**       0.50/4.07E−34       2.83E−18
                                                                                                                                            
  *Male Bipolar*                                                                                                                     
  ** Best Biomarkers**                                                                                                                      
  **  **[SPTBN1]{.ul}                                            M-BP       12/130          0.72/6.62E−03           0.21/8.54E−03       9.05E−03
  **  **C7orf73                                                  M-BP       12/130          0.75/2.38E−03          −0.17/2.76E−02       1.08E−04
  **  **BioM 54 Panel (Bonferroni List)                          M-BP       12/130          0.49/5.29E−01            0/4.90E−01         7.12E−01
  **  **BioM 12 Panel (Top Dozen List)                           M-BP       12/130          0.57/2.08E−01           0.08/1.78E−01       8.79E−02
  **  **BioM 2(SPTBN1 and C7orf73)                               M-BP       12/130          0.80/3.54E−04           0.23/4.77E−03       6.62E−05
   **Phenes**                                                                                                                               
  **  **Mood                                                     M-BP       12/130          0.8/3.65E−04           −0.47/6.83E−09       1.65E−03
  **  **Anxiety                                                  M-BP       12/130          0.86/2.19E−05           0.41/7.09E−07       1.91E−05
  **  **Mood and Anxiety (SASS)                                  M-BP       12/130          0.86/1.66E−05           0.5/7.15E−10        5.66E−05
  **  **CFI-S                                                    M-BP       12/128          0.92/1.10E−06           0.5/6.11E−10        1.31E−06
  **  **Mood and Anxiety, and CFI-S                              M-BP       12/128          0.94/2.82E−07           0.61/1.24E−14       3.01E−06
  ** Phenes and Biomarkers**                                                                                                                
  **  **Mood and Anxiety, and CFI-S and BioM 54                  M-BP       12/128          0.93/5.30E−07           0.61/1.78E−14       5.54E−06
  **  ***Mood and Anxiety, and CFI-S and BioM 12*                *M-BP*    *12/128*       *0.95/1.62E*−*07*       *0.62/1.92E*−*15*   *8.31E*−*07*
  **  **Mood and Anxiety, and CFI-S and BioM 2                   M-BP       12/128          0.97/5.14E−08           0.64/2.29E−16       2.59E−07

  *B. Future hospitalizations for suicidality in the first year following assessment*                                                                                      
  ------------------------------------------------------------------------------------- -------- ---------- --------------------------- ------------------- -------------- -------------------
  *Universal*                                                                                                                                                              
  ** Best Biomarkers**                                                                                                                                                               
  **  **[PSME4]{.ul}                                                                    All        38/471          0.59/2.62E−02           0.08/4.12E−02       6.20E−02      1.23/ 1.56E−01
  **  **AK2                                                                             All        38/471          0.60/2.31E−02          −0.06/9.70E−02       9.39E−03      1.35/ 7.22E−02
  **  **BioM 148 Panel (Bonferroni List)                                                All        38/471          0.52/3.37E−01          −0.02/6.67E−01       4.18E−01       1.09/8.27E−01
  **  **BioM 12 Panel (Top Dozen List)                                                  All        38/471          0.58/4.20E−02           0.05/1.47E−01       5.02E−02       1.88/1.41E−01
  **  **BioM 2 Panel (PSME4 and AK2)                                                    All        38/471          0.65/1.10E−03           0.10/1.29E−02       1.35E−03        1.68/0.018
  ** Phenes**                                                                                                                                                                        
  **  **Mood                                                                            All        38/471          0.65/1.00E−03          −0.16/3.63E−04       1.03E−03       1.69/1.47E−03
  **  **Anxiety                                                                         All        38/471      **0.69/3.70E**−**05**       0.16/3.43E−04       2.30E−04       1.82/2.62E−04
  **  **Mood and Anxiety (SASS)                                                         All        38/471      **0.71/9.78E**−**06**       0.18/4.89E−05       7.73E−05      1.45/ 8.11E−05
  **  **CFI-S                                                                           All        38/470      **0.75/1.79E**−**07**       0.2/5.11E−06        1.40E−06       2.02/7.11E−07
  **  **Mood and Anxiety and CFI-S                                                      All        38/470      **0.76/6.34E**−**08**       0.22/4.18E−07       2.22E−06       1.40/1.13E−07
  **  **HAMD SI                                                                         All       35/458\*     **0.81/5.27E**−**10**       0.40/1.57E−19       2.64E−06       2.10/1.11E−15
  **  **Mood and Anxiety, and CFI-S and HAMD SI                                         All       35/458\*     **0.82/9.96E**−**11**       0.35/4.11E−15       4.34E−08       1.36/1.83E−13
  ** Phenes and Biomarkers**                                                                                                                                                         
  **  **Mood and, Anxiety and CFI-S and BioM 148                                        All        38/470      **0.76/6.65E**−**08**       0.21/1.29E−06       2.29E−06       1.37/2.01E−07
  **  ***Mood and Anxiety, and CFI-S and BioM 12 (UP-Suicide)*                          *All*     *38/470*   ***0.77/2.87E***−***08***   *0.23/2.81E*−*07*   *9.11E*−*07*   *1.40/5.31E*−*08*
  **  **Mood and Anxiety, and CFI-S and BioM 2                                          All        38/470      **0.76/3.87E**−**08**       0.24/1.17E−07       1.02E−06       1.39/3.98E−08
  **  **Mood and Anxiety, and CFI-S and HAMD SI, and BioM 2                             All       35/458\*     **0.82/9.38E**−**11**       0.35/3.20E−15       3.39E−08       1.35/1.83E−13
                                                                                                                                                                                     
  *Male bipolars*                                                                                                                                                          
  ** Best biomarkers**                                                                                                                                                               
  **  **PTEN                                                                            M-BP       4/120           0.9/3.27E−03            0.22/6.76E−03       3.12E−02       1.73/2.73E−02
  **  **RNF6                                                                            M-BP       4/120           0.82/1.58E−02          −0.14/5.89E−02       9.14E−03       6.24/7.19E−02
  **  **BioM 54 Panel (Bonferroni List)                                                 M-BP       4/120           0.75/4.23E−02           0.11/1.23E−01       4.71E−02       4.58/2.52E−01
  **  **BioM 12 Panel (Top Dozen List)                                                  M-BP       4/120           0.56/3.41E−01           0.05/2.85E−01       3.08E−01       2.57/5.73E−01
  **  **BioM 2 (PTEN and RNF6)                                                          M-BP       4/120           0.94/1.50E−03           0.23/5.17E−03       3.06E−03       2.68/1.19E−02
  ** Phenes**                                                                                                                                                                        
  **  **Mood                                                                            M-BP       4/120           0.69/1.04E−01          −0.14/6.08E−02       1.75E−01       2.10/1.32E−01
  **  **Anxiety                                                                         M-BP       4/120           0.70/9.29E−02           0.12/9.74E−02       1.12E−01       1.87/2.09E−02
  **  **Mood and Anxiety (SASS)                                                         M-BP       4/120           0.72/7.19E−02           0.15/5.27E−02       1.34E−01       1.52/1.18E−01
  **  **CFI-S                                                                           MBP        4/120           0.80/2.10E−02           0.15/5.22E−02       3.46E−03       1.95/1.21E−01
  **  **Mood and Anxiety, and CFI-S                                                     M-BP       4/120           0.78/2.77E−02           0.18/2.36E−02       6.78E−02       1.41/5.54E−02
  ** Phenes and biomarkers**                                                                                                                                                         
  **  **Mood and Anxiety, and CFI-S and BioM 54                                         M-BP       4/120           0.81/1.64E−02           0.2/1.61E−02        5.13E−02       1.45/4.04E−02
  **  ***Mood and Anxiety, and CFI-S and BioM 12*                                       *M-BP*    *4/120*        *0.79/2.59E*−*02*       *0.19/1.88E*−*02*   *7.92E*−*02*   *1.44/4.72E*−*02*
  **  **Mood and Anxiety, and CFI-S and BioM 2                                          M-BP       4/120           0.86/7.02E−03           0.25/3.48E−03       2.22E−02       1.55/1.18E−2

[Biomarkers, phenes and combined predictions.]{.ul} Top increased and decreased individual predictive biomarkers. [Underlined]{.ul} are individual biomarkers from the Top Dozen list, the others are from the Bonferroni list. For Universal, the panel of Top Dozen biomarkers is called BioM 12, and the panel of Bonferroni biomarkers is called BioM148, reflecting the number of markers in the panel. For Male Bipolar, the panel of Top Dozen biomarkers is called BioM 12, and the panel of Bonferroni biomarkers is called BioM54, reflecting the number of markers in the panel. Bold, Bonferroni significant in the diagnostic testing. Italic, *a priori* primary endpoint (UP-Suicide).

Abbreviations: AUC, area under the curve; BP, bipolar; CFI-S, Convergent Functional Information for Suicidality; ROC, receiver operating characteristic; SASS, Simplified Affective State Scale; SI, suicidal ideation.

Bold *P*-value of AUC survives correction for multiple testing for predictions. ROC AUC is our *a priori* primary predictive tool. HAMD SI is the suicide rating question from the Hamilton Rating Scale for Depression.\*Smaller cohort, as not everybody had HAMD SI information.

###### Biological pathways

  *A. Universal biomarkers*                                                                                                                                                                                                                   
  ------------------------------------------------------------------- --- ---------------------------------------------- ---- ----- ---------- -------------------------------- --- ----- ---------- ----------------------------- ---------- --------------
  Validation Bonferroni significant (*n*=130 genes, 148 probe sets)   1   Regulation of neurogenesis                     8    6.6   2.10E−04   Tryptophan metabolism            4   0.2   1.10E−02   Protein kinase A signaling    4.36E−06   0.031 12/386
                                                                      2   Negative regulation of apoptosis               11   9     2.60E−04   Neurotrophin signaling pathway   6   0.3   1.40E−02   IGF-1 signaling               2.86E−05   0.062 35/582
                                                                      3   Negative regulation of programmed cell death   11   9     2.90E−04   Insulin signaling pathway        6   0.3   1.90E−02   Gap junction signaling        4.66E−05   0.045 7/155
                                                                      4   Negative regulation of cell death              11   9     3.00E−04   Butanoate metabolism             3   0.2   5.90E−02   Renin-angiotensin signaling   5.52E−05   0.055 6/109
                                                                      5   Regulation of cell morphogenesis               7    5.7   3.90E−04   Endocytosis                      6   0.3   6.10E−02   Hepatic cholestasis           5.93E−05   0.043 7/161

  *B. Male Bipolar biomarkers*                                                                                                                                                                                                                          
  ------------------------------ --- ---------------------------------------------------------------- --- ------ ---------- -------------------------------------- ---- ----- ---------- --------------------------------------------------- ---------- --------------
                                 1   Negative regulation of neuron differentiation                    7   14.6   9.30E−06   mTOR signaling pathway                 3    6.2   1.60E−02   G-protein coupled receptor signaling                1.14E−14   0.113 29/256
                                 2   Negative regulation of neurogenesis                              7   14.6   3.60E−05   Small cell lung cancer                 3    6.2   3.20E−02   CREB signaling in neurons                           1.98E−14   0.14 24/171
                                 3   Negative regulation of nervous system development                7   14.6   5.50E−05   Leukocyte transendothelial migration   3    6.2   5.80E−02   Neuropathic pain signaling in dorsal horn neurons   4.82E−13   0.18 18/100
                                 4   Positive regulation of protein localization to plasma membrane   4   8.3    1.10E−04   Sphingolipid signaling pathway         3    6.2   6.00E−02   14-3-3-mediated signaling                           7.79E−12   0.154 18/117
                                 5   Positive regulation of protein localization to cell periphery    4   8.3    1.10E−04   NA                                     NA   NA    NA         Gap junction signaling                              1.50E−11   0.129 20/155

Abbreviations: GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; NA, not applicable.

###### Step 6: Therapeutics

                                                                                  *Discovery (change) method/score*   *Prioritization total CFG score for suicide*   *Validation ANOVA* P*-value*  *Omega-3*                       *Lithium*                              *Clozapine*                                *Antidepressants*                                     *Other mood stabilizers*                 *Other other antipsychotics*
  ------------------------------------------------------------------------------ ----------------------------------- ---------------------------------------------- ------------------------------ ------------------------------- -------------------------------------- ------------------------------------------ ----------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  *Universal Top Dozen biomarkers*                                                                                                                                                                                                                                                                                                                                                                                  
   HTR2A 5-Hydroxytryptamine (serotonin) receptor 2A, G protein-coupled                      \(I\) DE/2                                    10                                     NS                                               \(D\) NT2.D1 cells Lithium^[@bib58]^   \(D\) PFC Clozapine^[@bib59],\ [@bib60]^   Blocked by: Mirtazapine, Amitriptyline                \(D\) NT2.D1 cells Valproate^[@bib58]^   \(D\) PFC Haloperidol^[@bib59]^ Blocked by: Paliperidone, Risperidone, Iloperidone, Asenapine, Cariprazine, Lurasidone, Quetiapine, Olanzapine
   IFNG Interferon, gamma                                                                    \(D\) AP/1                                    9                                      NS                                                                                                                                                                                                                                \(I\) Saliva, Blood Olanzapine, Risperidone, Quetiapine, Aripiprazole^[@bib61]^
   SLC4A4 Solute carrier family 4 (sodium bicarbonate cotransporter), member 4               \(I\) AP/1                                    7                                   7.74E−05                                                                                                                                                                                    \(D\) AMY, CP Valproate^[@bib62]^         
   CCL28 Chemokine (C--C motif) ligand 28                                                    \(D\) AP/4                                    4                                      NS                                                                                                                                 \(I\) Lymphoblastoid cell line Paroxetine^[@bib63]^                                             
                                                                                                                                                                                                                                                                                                                                                                                                                     
  *Male bipolar top dozen biomarkers*                                                                                                                                                                                                                                                                                                                                                                               
   HTR2A 5-Hydroxytryptamine (serotonin) receptor 2A, G protein-coupled                      \(I\) DE/2                                    10                                     NS                                               \(D\) NT2.D1 cells Lithium^[@bib58]^   \(D\) PFC Clozapine^[@bib59],\ [@bib60]^   Blocked by: Mirtazapine, Amitriptyline                \(D\) NT2.D1 cells Valproate^[@bib58]^   \(D\) PFC Haloperidol^[@bib59]^ Blocked by: Paliperidone, Risperidone, Iloperidone, Asenapine, Cariprazine, Lurasidone, Quetiapine, Olanzapine
   SAT1 Spermidine/spermine N1-acetyltransferase 1                                           \(I\) DE/2                                    8                                   4.06E−34            \(D\) blood Omega 3^[@bib64]^                                                                                                                                                                                     
   SPTBN1 Spectrin, beta, non-erythrocytic 1                                                 \(I\) AP/1                                    5                                   6.7E−32             \(D\) blood Omega 3^[@bib64]^                                                                                                                                                                                     

**[Pharmacogenomics]{.ul}**. Top Dozen lists biomarkers in our datasets that are targets of existing drugs and are modulated by them in opposite direction.

Abbreviations: ANOVA, analysis of variance; CFG, Convergent Functional Genomics; NS, non-stepwise in validation; PFC, prefrontal cortex.

###### Step 6: Therapeutics. New drug discovery/repurposing

  *A. CMAP analysis with the universal Top Dozen biomarkers signature*                                                    
  ---------------------------------------------------------------------- ------------------ ---------------------- ------ --------
  6086                                                                   Torasemide         11 μ[M]{.smallcaps}    MCF7   −0.9
  6087                                                                   Tenoxicam          12 μ[M]{.smallcaps}    MCF7   −0.9
  6088                                                                   Halcinonide        9 μ[M]{.smallcaps}     PC3    −0.902
  6089                                                                   Tretinoin          1 μ[M]{.smallcaps}     MCF7   −0.913
  6090                                                                   NU-1025            100 μ[M]{.smallcaps}   MCF7   −0.915
  6091                                                                   Abamectin          5 μ[M]{.smallcaps}     MCF7   −0.919
  6092                                                                   Prednicarbate      8 μ[M]{.smallcaps}     MCF7   −0.921
  6093                                                                   Tolmetin           13 μ[M]{.smallcaps}    MCF7   −0.924
  6094                                                                   Alprostadil        10 μ[M]{.smallcaps}    PC3    −0.925
  6095                                                                   [Amoxapine]{.ul}   13 μ[M]{.smallcaps}    MCF7   −0.927
  6096                                                                   Fenbufen           16 μ[M]{.smallcaps}    MCF7   −0.929
  6097                                                                   Sertaconazole      8 μ[M]{.smallcaps}     PC3    −0.93
  6098                                                                   Oxybuprocaine      12 μ[M]{.smallcaps}    MCF7   −0.961
  6099                                                                   **Piracetam**      28 μ[M]{.smallcaps}    MCF7   −0.973
  6100                                                                   **Ebselen**        15 μ[M]{.smallcaps}    PC3    −1

  *B. CMAP analysis with the universal Bonferroni biomarkers signature*                                                       
  ----------------------------------------------------------------------- ---------------------- --------------------- ------ --------
  6068                                                                    [Fluoxetine]{.ul}      12 μ[M]{.smallcaps}   HL60   −0.812
  6069                                                                    Betulin                9 μ[M]{.smallcaps}    HL60   −0.812
  6070                                                                    Netilmicin             3 μ[M]{.smallcaps}    HL60   −0.82
  6071                                                                    Dl-alpha tocopherol    9 μ[M]{.smallcaps}    HL60   −0.821
  6072                                                                    Haloperidol            10 μ[M]{.smallcaps}   HL60   −0.823
  6073                                                                    Streptozocin           15 μ[M]{.smallcaps}   HL60   −0.824
  6074                                                                    Hesperidin             7 μ[M]{.smallcaps}    HL60   −0.824
  6075                                                                    Calcium folinate       8 μ[M]{.smallcaps}    MCF7   −0.825
  6076                                                                    Harpagoside            8 μ[M]{.smallcaps}    MCF7   −0.826
  6077                                                                    Trimipramine           10 μ[M]{.smallcaps}   HL60   −0.836
  6078                                                                    Dapsone                16 μ[M]{.smallcaps}   HL60   −0.844
  6079                                                                    Fulvestrant            10 n[M]{.smallcaps}   HL60   −0.845
  6080                                                                    Rilmenidine            8 μ[M]{.smallcaps}    HL60   −0.845
  6081                                                                    Atractyloside          5 μ[M]{.smallcaps}    HL60   −0.849
  6082                                                                    Tenoxicam              12 μ[M]{.smallcaps}   HL60   −0.851
  6083                                                                    Chlorpromazine         11 μ[M]{.smallcaps}   HL60   −0.852
  6084                                                                    Harman                 18 μ[M]{.smallcaps}   HL60   −0.858
  6085                                                                    Homatropine            11 μ[M]{.smallcaps}   HL60   −0.863
  6086                                                                    Ramifenazone           14 μ[M]{.smallcaps}   HL60   −0.864
  6087                                                                    [Clozapine]{.ul}       10 μ[M]{.smallcaps}   HL60   −0.866
  6088                                                                    Diphenhydramine        14 μ[M]{.smallcaps}   HL60   −0.873
  6089                                                                    Metrizamide            5 μ[M]{.smallcaps}    HL60   −0.874
  6090                                                                    Prochlorperazine       7 μ[M]{.smallcaps}    HL60   −0.874
  6091                                                                    Pirenperone            10 μ[M]{.smallcaps}   HL60   −0.876
  6092                                                                    Hydrastinine           16 μ[M]{.smallcaps}   HL60   −0.88
  6093                                                                    Carbimazole            21 μ[M]{.smallcaps}   HL60   −0.884
  6094                                                                    Asiaticoside           4 μ[M]{.smallcaps}    HL60   −0.886
  6095                                                                    Procainamide           15 μ[M]{.smallcaps}   HL60   −0.894
  096                                                                     Ozagrel                15 μ[M]{.smallcaps}   HL60   −0.903
  6097                                                                    Adiphenine             11 μ[M]{.smallcaps}   HL60   −0.923
  6098                                                                    Merbromin              5 μ[M]{.smallcaps}    HL60   −0.924
  6099                                                                    **Metformin**          24 μ[M]{.smallcaps}   HL60   −0.983
  6100                                                                    **Chlorogenic acid**   11 μ[M]{.smallcaps}   HL60   −1

  *C. CMAP analysis with the male bipolar Top Dozen biomarkers signature*                                                        
  ------------------------------------------------------------------------- ----------------------- --------------------- ------ --------
  6086                                                                      Harmaline               14 μ[M]{.smallcaps}   MCF7   −0.822
  6087                                                                      Foliosidine             13 μ[M]{.smallcaps}   MCF7   −0.834
  6088                                                                      3-Nitropropionic acid   10 μ[M]{.smallcaps}   MCF7   −0.844
  6089                                                                      Biperiden               11 μ[M]{.smallcaps}   PC3    −0.844
  6090                                                                      Carisoprodol            15 μ[M]{.smallcaps}   HL60   −0.848
  6091                                                                      Nalidixic acid          15 μ[M]{.smallcaps}   MCF7   −0.861
  6092                                                                      Eucatropine             12 μ[M]{.smallcaps}   PC3    −0.869
  6093                                                                      Solasodine              10 μ[M]{.smallcaps}   PC3    −0.873
  6094                                                                      Dicoumarol              12 μ[M]{.smallcaps}   PC3    −0.875
  6095                                                                      Pivampicillin           9 μ[M]{.smallcaps}    MCF7   −0.879
  6096                                                                      Gabexate                10 μ[M]{.smallcaps}   PC3    −0.885
  6097                                                                      Dacarbazine             22 μ[M]{.smallcaps}   PC3    −0.892
  6098                                                                      Prestwick-692           7 μ[M]{.smallcaps}    MCF7   −0.927
  6099                                                                      **Carteolol**           12 μ[M]{.smallcaps}   HL60   −0.946
  6100                                                                      **Betulin**             9 μ[M]{.smallcaps}    HL60   −1

  *D. CMAP analysis with the male bipolar Bonferroni biomarkers signature*                                                          
  -------------------------------------------------------------------------- ------------------------ ---------------------- ------ --------
  6068                                                                       [Valproic acid]{.ul}     50 μ[M]{.smallcaps}    MCF7   −0.799
  6069                                                                       Ondansetron              12 μ[M]{.smallcaps}    PC3    −0.802
  6071                                                                       NU-1025                  100 μ[M]{.smallcaps}   MCF7   −0.807
  6073                                                                       Glycopyrronium bromide   10 μ[M]{.smallcaps}    PC3    −0.814
  6074                                                                       Triflupromazine          10 μ[M]{.smallcaps}    HL60   −0.817
  6075                                                                       Suxibuzone               9 μ[M]{.smallcaps}     MCF7   −0.819
  6076                                                                       Mepyramine               10 μ[M]{.smallcaps}    MCF7   −0.822
  6079                                                                       Hydrocortisone           11 μ[M]{.smallcaps}    MCF7   −0.837
  6080                                                                       Benfotiamine             9 μ[M]{.smallcaps}     PC3    −0.839
  6082                                                                       Deferoxamine             6 μ[M]{.smallcaps}     PC3    −0.841
  6084                                                                       Homatropine              11 μ[M]{.smallcaps}    MCF7   −0.845
  6085                                                                       Nifedipine               12 μ[M]{.smallcaps}    PC3    −0.849
  6086                                                                       Alpha-ergocryptine       7 μ[M]{.smallcaps}     MCF7   −0.862
  6088                                                                       Meclozine                9 μ[M]{.smallcaps}     MCF7   −0.875
  6089                                                                       Acacetin                 14 μ[M]{.smallcaps}    PC3    −0.882
  6095                                                                       Fenoprofen               7 μ[M]{.smallcaps}     PC3    −0.933
  6096                                                                       CP-690334-01             1 μ[M]{.smallcaps}     MCF7   −0.936
  6097                                                                       Baclofen                 19 μ[M]{.smallcaps}    PC3    −0.94
  6098                                                                       Chlorambucil             13 μ[M]{.smallcaps}    MCF7   −0.945
  6099                                                                       **Naproxen**             16 μ[M]{.smallcaps}    PC3    −0.96
  6100                                                                       **Chlorphenesin**        16 μ[M]{.smallcaps}    HL60   −1

Connectivity Map^[@bib65],\ [@bib66]^ (CMAP) analysis, drugs that have opposite gene expression profile effects to our suicide biomarkers signatures. A score of −1 indicates the perfect opposite match, that is, the best potential therapeutic for suicidality. Underlined, drugs known to treat mood disorders and suicidality, which thus serve as a *de facto* positive control for our approach. Bold means top compounds of interest, pharmaceutical and natural.
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